Want to join the conversation?
$BMY 2Q15 Q&A: Rubin, of Goldman Sachs enquired about investment spending in IO and timing of bottom line leverage. Charlie responded that BMY sees IO opportunity as its opportunity to continue to reinforce leadership in IO and that opportunity will ultimately improve leverage for the back-end of the decade.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.